Prescient strengthens ties with leading CAR-T research centre
Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its...
Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its...
Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre...
With the number of days left to file March quarterly reports running a little short...
Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion...
When JVC launched VHS videos in 1971, it started a consumer revolution that permanently altered...
Two ASX-listed ventures are among the companies now investing billions of dollars to develop an...
The burgeoning CAR T therapy industry has passed another significant milestone after the US Food...
Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.